{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:09:53Z","timestamp":1788365393524,"version":"build-2803163510"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cutaneous immune-related adverse events are frequently associated with immune checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal antibodies bind the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1\/ligand 1 leading to a non-specific activation of the immune system against both tumoral cells and self-antigens. The skin is the most frequently affected organ system appearing involved especially by inflammatory manifestations such as maculopapular, lichenoid, psoriatic, and eczematous eruptions. Although less common, ICI-induced autoimmune blistering diseases have also been reported, with an estimated overall incidence of less than 5%. Bullous pemphigoid-like eruption is the predominant phenotype, while lichen planus pemphigoides, pemphigus vulgaris, and mucous membrane pemphigoid have been described anecdotally. Overall, they have a wide range of clinical presentations and often overlap with each other leading to a delayed diagnosis. Achieving adequate control of skin toxicity in these cases often requires immunosuppressive systemic therapies and\/or interruption of ICI treatment, presenting a therapeutic challenge in the context of cancer management. In this study, we present a case series from Italy based on a multicenter, retrospective, observational study, which included 45 patients treated with ICIs who developed ICI-induced bullous pemphigoid. In addition, we performed a comprehensive review to identify the cases reported in the literature on ICI-induced autoimmune bullous diseases. Several theories seeking their underlying pathogenesis have been reported and this work aims to better understand what is known so far on this issue.<\/jats:p>","DOI":"10.3389\/fmed.2023.1208418","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:08:24Z","timestamp":1689926904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience"],"prefix":"10.3389","volume":"10","author":[{"given":"Martina","family":"Merli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Accorinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Romagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Sollena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Teoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ardig\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Michelerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna Rita","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Dika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e000356","DOI":"10.1136\/jitc-2019-000356","article-title":"Immunotherapy to treat malignancy in patients with pre-existing autoimmunity","volume":"8","author":"Boland","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"103376","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced Cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1111\/ced.15332","article-title":"Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies","volume":"47","author":"Seervai","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of Cutaneous Immune-Related Adverse Events with Increased Survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jaad.2021.03.024","article-title":"Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors","volume":"86","author":"Thompson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e15747","DOI":"10.1111\/dth.15747","article-title":"Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma","volume":"35","author":"Shreberk-Hassidim","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.3390\/jcm11123364","article-title":"Identifying candidates for immunotherapy among patients with non-melanoma skin Cancer: a review of the potential predictors of response","volume":"11","author":"Zelin","year":"2022","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"45817","DOI":"10.5070\/D32510045817","article-title":"Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature","volume":"25","author":"Kosche","year":"2019","journal-title":"Dermatol Online J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and Meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaad.2018.09.048","article-title":"Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis","volume":"85","author":"Kridin","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2021.09.032","article-title":"Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid","volume":"159","author":"Shi","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/ijd.15796","article-title":"Bullous pemphigoid probably associated with pembrolizumab: a case of delayed toxicity","volume":"61","author":"Correia","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e15948","DOI":"10.1111\/dth.15948","article-title":"Intravenous immunoglobulin for pembrolizumab-induced bullous pemphigoid-like eruption: a case report","volume":"35","author":"Hoshina","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1111\/jdv.17321","article-title":"Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors","volume":"35","author":"Povilaityte","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ajd.13960","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a case series of 13 patients","volume":"64","author":"Yun","year":"","journal-title":"Aust J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e28199","DOI":"10.1097\/MD.0000000000028199","article-title":"Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma","volume":"100","author":"Huynh","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"57396","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni","year":"2022","journal-title":"Dermatol Online J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e15466","DOI":"10.1111\/dth.15466","article-title":"Self-resolving bullous pemphigoid induced by cemiplimab","volume":"35","author":"Molle","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e24804","DOI":"10.7759\/cureus.24804","article-title":"A case of bullous pemphigoid associated with Nivolumab therapy","volume":"14","author":"Gotera","year":"2022","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"984132","DOI":"10.3389\/fimmu.2022.984132","article-title":"Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: a case report","volume":"13","author":"Mari","year":"2022","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e15623","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/cup.14183","article-title":"Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male","volume":"49","author":"Alvarado","year":"2022","journal-title":"J Cutan Pathol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"731774","DOI":"10.3389\/fimmu.2021.731774","article-title":"Case report: a rare case of Pembrolizumab-induced bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"27(9)","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","article-title":"Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid","volume":"88","author":"Said","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1684\/ejd.2021.4052","article-title":"Dyshidrosiform pemphigoid due to nivolumab therapy","volume":"31","author":"Hayashi","year":"2021","journal-title":"Eur J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/dermatopathology9010010","article-title":"Bullous pemphigoid in patients receiving immune-checkpoint inhibitors and psoriatic patients-focus on clinical and histopathological variation","volume":"9","author":"Niebel","year":"2022","journal-title":"Dermatopathology (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1111\/ijd.16068","article-title":"Bullous pemphigoid associated with Grover disease: a specific toxicity of anti-PD-1 therapies?","volume":"61","author":"Jendoubi","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"953546","DOI":"10.3389\/fimmu.2022.953546","article-title":"Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid-a retrospective, monocentric study","volume":"13","author":"Schauer","year":"2022","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/RLU.0000000000003894","article-title":"Immunotherapy (Cemiplimab)-induced bullous pemphigoid: a possible pitfall in 18F-FDG PET\/CT","volume":"47","author":"Gr\u00fcnig","year":"2022","journal-title":"Clin Nucl Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ddg.13411_g","article-title":"Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma","volume":"16","author":"Amber","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/ced.15177","article-title":"The iso-oncotopic response: immunotherapy-associated bullous pemphigoid in tumour footprints","volume":"47","author":"Pearlman","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid with Immune Checkpoint Inhibitor Therapy in patients with Cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e21770","DOI":"10.7759\/cureus.21770","article-title":"Bullous pemphigoid associated with Pembrolizumab therapy for non-small-cell lung Cancer: a case report","volume":"14","author":"Chatterjee","year":"2022","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1078155220946370","article-title":"Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: a case report and review of literature","volume":"27","author":"Cosimati","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2022.06.026","article-title":"A 72-year-old man with nonhealing facial erosions and bullae","volume":"27","author":"Pan","year":"2022","journal-title":"JAAD Case Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers14215451","article-title":"A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: a national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-programmed death-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/jcm10040728","article-title":"The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes","volume":"10","author":"Hashimoto","year":"2021","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed Death-1\/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after Pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"103036","DOI":"10.1016\/j.autrev.2022.103036","article-title":"Mucous membrane pemphigoid","volume":"21","author":"Du","year":"2022","journal-title":"Autoimmun Rev"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/jdv.16036","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"F\u00e4ssler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/CJI.0000000000000280","article-title":"A severe, refractory case of mucous membrane pemphigoid after treatment with Pembrolizumab: brief communication","volume":"42","author":"Bezinelli","year":"2019","journal-title":"J Immunother"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/j.oooo.2021.05.012","article-title":"Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events","volume":"132","author":"Duan","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e14109","DOI":"10.1111\/dth.14109","article-title":"Mucous membrane pemphigoid in a patient treated with nivolumab for Hodgkin\u2019s lymphoma","volume":"33","author":"Durmus","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"00429","DOI":"10.1016\/j.jvoice.2022.12.028","article-title":"Laryngeal mucous membrane pemphigoid as an immune-related adverse effect of Pembrolizumab treatment","author":"Lagos-Villaseca","year":"2023","journal-title":"J Voice"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/ajd.13808","article-title":"Challenges and pitfalls between lichen planus pemphigoides and bullous lichen planus","volume":"63","author":"Papara","year":"2022","journal-title":"Australas J Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3389\/fimmu.2019.01389","article-title":"Lichen planus Pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering","volume":"10","author":"H\u00fcbner","year":"2019","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","article-title":"Lichen planus Pemphigoides associated with PD-1 and PD-L1 inhibitors: a case series and review of the literature","volume":"44","author":"Boyle","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"804","DOI":"10.47102\/annals-acadmedsg.2022134","article-title":"Lichen planus pemphigoides after pembrolizumab immunotherapy in an older man","volume":"51","author":"Ee","year":"2022","journal-title":"Ann Acad Med Singap"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eucr.2018.11.008","article-title":"Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - a case report","volume":"23","author":"Lindner","year":"2019","journal-title":"Urol Case Rep"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2050313X2199327","DOI":"10.1177\/2050313X21993279","article-title":"A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: a case report","volume":"9","author":"Manko","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/pde.15097","article-title":"A case of severe nivolumab-induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma","volume":"40","author":"Mueller","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdcr.2022.08.030","article-title":"Pembrolizumab-induced rash in a patient with angiosarcoma","volume":"29","author":"Qian","year":"2022","journal-title":"JAAD Case Rep"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e15432","DOI":"10.1111\/dth.15432","article-title":"Lichen planus pemphigoides: a unique form of bullous and lichenoid eruptions secondary to nivolumab","volume":"35","author":"Shah","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/1346-8138.15693","article-title":"Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment","volume":"48","author":"Sugawara","year":"2021","journal-title":"J Dermatol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/cup.14299","article-title":"Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J Cutan Pathol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1111\/1346-8138.16006","article-title":"Lichen planus pemphigoides with antibodies against the BP180 C-terminal domain induced by pembrolizumab in a melanoma patient","volume":"48","author":"Yoshida","year":"2021","journal-title":"J Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/ddg.13272_g","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref72","first-page":"224","article-title":"Nivolumab-induced lichen planus pemphigoides","volume":"103","author":"Strickley","year":"2019","journal-title":"Cutis"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1111\/1346-8138.14906","article-title":"Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab","volume":"46","author":"Sato","year":"2019","journal-title":"J Dermatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/1346-8138.15461","article-title":"Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma","volume":"47","author":"Okada","year":"2020","journal-title":"J Dermatol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jdcr.2020.03.007","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma","volume":"6","author":"Kwon","year":"2020","journal-title":"JAAD Case Rep"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1111\/1346-8138.15248","article-title":"Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer","volume":"47","author":"Senoo","year":"2020","journal-title":"J Dermatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/ajd.13214","article-title":"Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer","volume":"61","author":"Kerkemeyer","year":"2020","journal-title":"Australas J Dermatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"691980","DOI":"10.3389\/fonc.2021.691980","article-title":"Case report: autoimmune pemphigus vulgaris in a patient treated with Cemiplimab for multiple locally advanced cutaneous squamous cell carcinoma","volume":"11","author":"Buquicchio","year":"2021","journal-title":"Front Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clindermatol.2011.01.016","article-title":"Drug-induced pemphigus","volume":"29","author":"Brenner","year":"2011","journal-title":"Clin Dermatol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1111\/1346-8138.14601","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume":"46","author":"Ito","year":"2019","journal-title":"J Dermatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1111\/ijd.15405","article-title":"Pemphigus associated with ipilimumab therapy","volume":"60","author":"Schoenberg","year":"2021","journal-title":"Int J Dermatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fmed.2019.00262","article-title":"Recurrence of pemphigus vulgaris under Nivolumab therapy","volume":"6","author":"Krammer","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"e14871","DOI":"10.1111\/dth.14871","article-title":"Pemphigus vulgaris flare in a patient treated with nivolumab","volume":"34","author":"Clawson","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00403-017-1790-8","article-title":"Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus","volume":"310","author":"Tavakolpour","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed Death-1 pathway inhibitors among patients with non-small-cell lung Cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/ijd.13713","article-title":"Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus","volume":"56","author":"Maeda","year":"2017","journal-title":"Int J Dermatol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.oraloncology.2003.09.020","article-title":"Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations","volume":"40","author":"Kaplan","year":"2004","journal-title":"Oral Oncol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdcr.2021.02.012","article-title":"Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma","volume":"10","author":"McNally","year":"2021","journal-title":"JAAD Case Rep"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic pemphigus revealed by anti-programmed Death-1 Pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis Suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.3390\/jcm10143047","article-title":"Cutaneous events associated with immunotherapy of melanoma: a review","volume":"10","author":"Burzi","year":"2021","journal-title":"J Clin Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Onco Targets Ther"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat Immunol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAI.0b013e318162f8aa","article-title":"Collagen XVII\/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy","volume":"16","author":"Stelkovics","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00418-012-0981-9","article-title":"Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis","volume":"138","author":"Krenacs","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1074\/jbc.R400034200","article-title":"Collagenous transmembrane proteins: recent insights into biology and pathology*","volume":"280","author":"Franzke","year":"2005","journal-title":"J Biol Chem"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"e10566","DOI":"10.1371\/journal.pone.0010566","article-title":"Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma","volume":"5","author":"Shimbo","year":"2010","journal-title":"PLoS One"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ijc.2910590413","article-title":"HLA-DQB1*0301 association with increased cutaneous melanoma risk","volume":"59","author":"Lee","year":"1994","journal-title":"Int J Cancer"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-associated bullous pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:08:36Z","timestamp":1689926916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":107,"alternative-id":["10.3389\/fmed.2023.1208418"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1208418","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"article-number":"1208418"}}